

App. No. 10/523,477

Docket No. EX03-051C-PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of Gendreau, *et al.*

Application No.: 10/523,477

Filed: February 4, 2005

For: MAXS AS MODIFIERS OF THE AXIN
PATHWAY AND METHODS OF USE

Confirmation No.: 2298

Attorney Docket No.: EX03-051C-PC

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant notes that Citation Nos. 15 through 20 of the Information Disclosure Statement in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application.


In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.

In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required, as the disclosure is delivered within three months of the date of entry of the national stage. However, the Commissioner is authorized to charge any required fees, to deposit account no. 50-1108.

Respectfully submitted,

Dated: March 21, 2005


Laleh Shayanfar Reg. No. 47,937
Tel. (650) 837-8223; Fax: (650) 837-8234

App. No. 10/523,477
Docket No. EX03-051C-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Gendreau, *et al.*

Application No.: 10/523,477

Filed: February 4, 2005

For: MAXS AS MODIFIERS OF THE AXIN
PATHWAY AND METHODS IF USE

Confirmation No.: 2298

Attorney Docket No.: EX03-051C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:


US6335169, Dai, Wei, et al., 01-01-2002
US6489137, Seeley, Todd W., 12-03-2002
US6593098, Yen, Timothy, et al., 07-15-2003

The above-references have **not** been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: March 21, 2005



Laleh Shayesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/523,477 |
| Filing Date | February 4, 2005 |
| First Named Inventor | Gendreau |
| Art Unit | Not yet assigned |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | EX03-051C-US |

NON PATENT LITERATURE DOCUMENTS


| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|--|----------------|
| | 1 | LEE,K., et al., "Homo sapiens membrane-bound transcription factor protease, site 2 (MBTPS2), mRNA.", Genbank GI No. 7706692 [online], 28-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 2 | GRUNEGERG,U., et al., "Homo sapiens aurora kinase B (AURKB), mRNA.", Genbank GI No. 4759177 [online], 26-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 3 | KIMURA,M., et al., "Homo sapiens aurora kinase C (AURKC), mRNA.", Genbank GI No. 4507272 [online], 28-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 4 | KIMURA,M., et al., "Homo sapiens serine/threonine kinase 6 (STK6), mRNA.", Genbank GI No. 4507278 [online], 31-OCT-2000 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 5 | SHIN,H.J., et al., "Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) (BUB1B), mRNA.", Genbank GI No. 20149508 [online], 27-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 6 | DOAK,S.H., et al., "Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA.", Genbank GI No. 4757877 [online], 28-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 7 | SAKAI,Y., et al., "Homo sapiens retinoblastoma binding protein 6 (RBBP6), mRNA.", Genbank GI No. 5902043 [online], 06-APR-2003 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=nucleotide> | |
| | 8 | LEE,K., et al., "membrane-bound transcription factor protease, site 2 [Homo sapiens].", Genbank GI No. 7706693 [online], 28-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein> | |
| | 9 | GRUNEBERG,U., et al., "aurora kinase B [Homo sapiens].", Genbank GI No. 4759178 [online], 26-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein> | |
| | 10 | KIMURA,M., et al., "aurora kinase C [Homo sapiens].", Genbank GI No. 4507273 [online], 28-OCT-2004 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein> | |
| | 11 | LI,D., et al., "serine/threonine kinase 6; serine/threonine protein kinase-6; aurora-A; IPL1-related kinase [Homo sapiens].", Genbank GI No. 4507275 [online], 05-OCT-2003 [retrieved 1/12/05]. Retrieved from the Internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein> | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/523,477 |
| Filing Date | February 4, 2005 |
| First Named Inventor | Gendreau |
| Art Unit | Not yet assigned |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | EX03-051C-US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|--|----------------|
| | 12 | CHAN, G.K., et al., "BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast); hBUBR1; budding uninhibited by benzimidazoles 1 (yeast homolog), beta [Homo sapiens].", Genbank GI No. 5729750 [online], 19-DEC-2001 [retrieved 1/12/05]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein > | |
| | 13 | TANG, Z., et al., "BUB1 budding uninhibited by benzimidazoles 1 homolog [Homo sapiens].", Genbank GI No. 4757878 [online], 20-DEC-2004 [retrieved 1/12/05]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein > | |
| | 14 | SAKAI, Y., et al., "retinoblastoma-binding protein 6 [Homo sapiens].", Genbank GI No. 5902044 [online], 06-APR-2003 [retrieved 1/12/05]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=protein > | |
| | 15 | RUI, H.-L., et al., "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling.", J. Biol. Chem., 08 November 2002, p42981-6, 227-45. | |
| | 16 | RUIZ, S., et al., "Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis.", Developmental Dynamics, 2004, p410-18, 230. | |
| | 17 | SHIBAMOTO, S., et al., "A blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells.", Experimental Cell Research, 2004, p11-20, 292. | |
| | 18 | HSU, W., et al., "Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice.", J. Cell Biol., 10 December 2001, p1055-64, 155-6. | |
| | 19 | NISHIDA, T., et al., "Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat Axam, which is an Axin-binding protein promoting beta-catenin degradation.", J. Biol. Chem., 19 October 2001, p39060-6, 276-42. | |
| | 20 | KADOYA, T., et al., "Inhibition of Wnt signaling pathway by a novel Axin-binding protein.", J. Biol. Chem., 24 November 2000, 37030-7, 275-47 | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.